Medicare Enrolled

Dr. David Goldberg, MD, FAAP

Neuro-ophthalmology Physician · Wyomissing, PA
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Speaking/Promotional
1 GRANITE POINT DR STE 100, Wyomissing, PA 19610
6103781344
In practice since 2006 (20 years)
NPI: 1578543781 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Goldberg from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Goldberg? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Goldberg

Dr. David Goldberg is a neuro-ophthalmology physician in Wyomissing, PA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Goldberg performed 4,014 Medicare services across 1,105 unique beneficiaries.

Between the years covered by Open Payments, Dr. Goldberg received a total of $4,509 from 21 pharmaceutical and/or device companies across 48 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in neuro-ophthalmology physician. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Goldberg is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice ▲ Top 33% volume in PA $4,509 industry payments

Medicare Practice Summary

Medicare Utilization ↗
4,014
Medicare services
Top 33% in PA for neuro-ophthalmology physician
1,105
Unique beneficiaries
$30
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~201 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Botox injection (Xeomin), per unit
An injection of incobotulinumtoxin A, a botulinum toxin type A product, administered in a quantity of one unit.
2,799 $4 $7
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
351 $65 $95
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
175 $85 $175
Office visit, established patient (10-19 min)
An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition.
144 $39 $60
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
69 $120 $220
Visual field test, extended
A test that maps your complete field of vision to detect blind spots or peripheral vision loss. Extended testing provides a more detailed assessment than a standard visual field exam.
54 $45 $100
Dilation of tear drainage opening
A procedure to widen the opening of the tear drainage system to improve the flow of tears from the eye.
52 $72 $375
Eye deviation and range of motion exam
An examination to measure eye deviation and assess the range of motion of the eyes.
45 $46 $100
Eye exam, established patient, focused
A limited examination of the visual system for an existing patient. The provider focuses on a specific eye-related concern or symptom.
43 $51 $120
New patient office visit (30-44 min)
An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range.
39 $72 $140
Chemical nerve block for facial paralysis
Injection of a chemical agent to paralyze specific nerves or muscles on the side of the face.
38 $146 $500
Removal of benign skin growth from face or mouth, 0.5 cm or less
This procedure involves the surgical removal of a noncancerous skin growth located on the face, ears, eyelids, nose, lips, or mouth. The growth removed is 0.5 centimeters in diameter or smaller.
33 $101 $330
Removal of excessive skin and fat of upper eyelid 31 $623 $3,200
Retinal imaging (OCT scan)
This procedure involves imaging the retina to visualize its structure. It is used to examine the back of the eye.
28 $31 $75
Optic nerve imaging (OCT scan)
Imaging of the optic nerve.
25 $26 $75
Removal of noncancer skin growth, face/ears/eyelids/nose/lips/mouth, 0.6-1.0 cm
This procedure involves the surgical removal of a benign skin growth from the face, ears, eyelids, nose, lips, or mouth. The growth removed measures between 0.6 and 1.0 centimeters in diameter.
18 $127 $422
New patient office visit, complex (60-74 min) 17 $156 $260
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
16 $128 $190
Upper eyelid muscle shortening or advancement
A surgical procedure to shorten or advance the upper eyelid muscle. It is performed to correct drooping or paralysis of the eyelid.
13 $382 $3,385
Comprehensive eye exam, established patient
A comprehensive examination of the visual system performed for a patient who has previously been seen by the provider.
13 $79 $170
Destruction of eyelid margin growth, 1.0 cm or less
This procedure involves the removal or destruction of a growth located on the margin of the eyelid that measures 1.0 centimeter or smaller.
11 $151 $640
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$4,509
Total received (2018-2024)
Avg $644/year across 7 years
Top 25% in PA for neuro-ophthalmology physician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
21
Companies
48
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$3,750 (83.2%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$759 (16.8%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$226
2023
$1,691
2022
$2,245
2021
$184
2020
$35
2019
$61
2018
$68

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$67
Astellas Pharma US Inc
$40
Regeneron Healthcare Solutions, Inc.
$34
Merz Pharmaceuticals, LLC
$31
Bausch & Lomb Americas Inc.
$21
Alcon Vision LLC
$19
ANI Pharmaceuticals, Inc.
$14
Top 3 companies account for 62.1% of 2024 payments
All-time payments by company (2018-2024) ›
Horizon Therapeutics plc
$3,891
Alcon Vision LLC
$73
Amgen Inc.
$67
Regeneron Healthcare Solutions, Inc.
$66
Bausch & Lomb Americas Inc.
$54
Merz Pharmaceuticals, LLC
$43
Shire North American Group Inc
$42
Astellas Pharma US Inc
$40
Merz North America, Inc.
$34
Aerie Pharmaceuticals, Inc.
$24
Allergan, Inc.
$23
Bausch & Lomb, a division of Bausch Health US, LLC
$22
Alimera Sciences, Inc.
$21
Rayner Intraocular Lenses Limited
$19
ARGENX US, INC.
$19
Omeros Corporation
$14
ANI Pharmaceuticals, Inc.
$14
Apellis Pharmaceuticals, Inc.
$14
EYEVANCE PHARMACEUTICALS LLC
$14
Spark Therapeutics, Inc.
$13
Retrophin, Inc.
$1
Top 3 companies account for 89.4% of all-time payments
Associated products mentioned in payments ›
(820) Cholbam · ACTIVEFOCUS · AcrySof IQ VIVITY IOL · Clareon · EYLEA · EYLEA HD · Flarex · ILUVIEN · INFUSE · Izervay · LUXTURNA · Omidria · PURIFIED CORTROPHIN GEL · Rhopressa · Syfovre · TEPEZZA · VUITY · VYVGART · VYZULTA · XEOMIN · XIIDRA · XIPERE · Xeomin
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (83%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in neuro-ophthalmology physician and does not inherently indicate bias, but patients may wish to be aware.

Looking for a neuro-ophthalmology physician in Wyomissing?
Compare neuro-ophthalmology physicians in the Wyomissing area by procedure volume, costs, and industry payment transparency.
Browse neuro-ophthalmology physicians nearby

Geographic Context

Neuro-ophthalmology physicians within 10 mi
1
Per 100K population
0.2
County median income
$77,684
Nearest hospital
SURGICAL INSTITUTE OF READING
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Goldberg is a clinical cardiology specialist, with moderate Medicare volume, with speaking/promotional industry engagement, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Goldberg experienced with botox injection (xeomin), per unit?
Based on Medicare claims data, Dr. Goldberg performed 2,799 botox injection (xeomin), per unit services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Goldberg receive payments from pharmaceutical companies?
Yes. Dr. Goldberg received a total of $4,509 from 21 companies across 48 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Goldberg's costs compare to other neuro-ophthalmology physicians in Wyomissing?
Dr. Goldberg's average Medicare payment per service is $30. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Goldberg) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →